SUMMIT TECHNOLOGY GRANTED LICENSE TO IBM PATENT
SUMMIT TECHNOLOGY GRANTED LICENSE TO IBM PATENT WALTHAM, Mass., March 2 /PRNewswire/ -- Summit Technology, Inc.
(NASDAQ: BEAM) announced today that IBM has granted Summit a license to IBM's patent no. 4,784,135 which covers basic methods of excimer laser tissue ablation. Under the license agreement, Summit will pay IBM 2 percent of the net sales price on ophthalmic excimer laser systems sold for use in the United States, Canada, Japan, Brazil, Australia and Spain.
These patent rights are a significant addition to Summit's intellectual property portfolio and further secure Summit's position as the leader in the ophthalmic refractive laser industry. Summit Technology, Inc. has established the leadership position in designing, manufacturing and marketing ophthalmic refractive laser systems. A major focus of the company's business is in ophthalmology where applications have been developed for the treatment of common vision disorders such as nearsightedness, farsightedness, astigmatism, glaucoma, and certain corneal irregularities due to disease or injury. There are believed to be approximately 140 million people in the United States with refractive disorders. To date, over 10,000 patients have been treated worldwide by ophthalmologists using Summit's laser systems. -0- 3/2/92 /CONTACT: Paula Rainville of Summit Technology, 617-890-1234/ (BEAM) CO: Summit Technology ST: Massachusetts IN: MTC SU:
DH-TM -- NE003 -- 3750 03/02/92 08:33 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 2, 1992|
|Previous Article:||HILTON TO ENTER RIVERBOAT GAMING|
|Next Article:||LIPPINCOTT CELEBRATES 200TH BIRTHDAY|